Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 15/20 | 1.00 |
| ▸ | TUBB | P07437 | 15/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 15/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 15/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 15/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 15/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 15/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 15/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 15/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 15/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 15/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 15/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 15/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 15/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 15/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 0.79 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | GHSR | Q92847 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18602043 | 0.90 | MLNR (0.91) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18602221 | 0.90 | MLNR (0.91) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Desacetylvinblastinehydrazide SCHEMBL29410063 | 0.89 | MLNR (0.90) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Desacetylvinblastinehydrazide SCHEMBL17529277 | 0.89 | MLNR (0.90) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Desacetylvinblastinehydrazide SCHEMBL29376353 | 0.89 | MLNR (0.90) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL19787808 | 0.89 | MLNR (0.90) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18602222 | 0.89 | MLNR (0.90) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL19443227 | 0.89 | MLNR (0.90) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13011060 | 0.89 | MLNR (0.90) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Desacetylvinblastinehydrazide SCHEMBL15507828 | 0.89 | MLNR (0.90) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-104244968-A | PH20 polypeptide variants, formulations, and uses thereof | HALOZYME INC | 2014-12-24 | — | — | CN | claimed |
| JP-2011528275-A | — | — | 2011-11-17 | — | — | JP | claimed |
| EP-2313122-A1 | DRUG DELIVERY MEDICAL DEVICE | Micell Technologies, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2010009335-A1 | DRUG DELIVERY MEDICAL DEVICE | MICELL TECHNOLOGIES, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| CN-100500218-C | Anti tumour medicinal composition | SHANDONG LANJIN BIOLOG ENGINEE (CN) | 2009-06-17 | — | — | CN | claimed |
| CN-101390827-A | Sustained-release injection containing methotrexate synergist | JINAN SHUAIHUA MEDICINE TECHNO (CN) | 2009-03-25 | — | — | CN | claimed |
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| CN-1846670-A | Anticancer implant | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1839817-A | Anticancer sustained-release injection containing taxane | JINAN SHUAIHUA MEDICINE TECHNO (CN) | 2006-10-04 | — | — | CN | claimed |
| CN-1824314-A | Slow-release agent containing hormone anticancer medicine | JINAN KANGQUAN MEDICINE SCI & (CN) | 2006-08-30 | — | — | CN | claimed |
| CN-1733302-A | Anticancer implantation agent | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | claimed |
| CN-1686544-A | Anti entity tumour medicinal composition containing plant alkaloid | SHANDONG LANJIN BIOLOG ENGINEE (CN) | 2005-10-26 | — | — | CN | claimed |
| CN-1686553-A | Anti entity tumour medicinal composition | SHANDONG LANJIN BIOLOG ENGINEE (CN) | 2005-10-26 | — | — | CN | claimed |
| CN-1679949-A | Anticarcinogenic internal implant agent | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1676165-A | In vivo slow-releasing anticancer medicinal composition | LANJIN BIOENGINEERING CO LTD S (CN) | 2005-10-05 | — | — | CN | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | SI, SLC29A2, SLC29A1 | TUBB4A 4057/4885TUBB 4051/4885TUBA3C 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.